11βHSD1 inhibitor use in human disease- a systematic review and narrative synthesis, page-13

I agree that they don't know, and that it would have been announced if they did know.

XanaHES suggests that 10mg was too low.
The half life suggests that once daily is sub-optimal.

Gazing at the XanADu results won't tell us the reason.
What kind of analysis are you suggesting?
There's been a separate target occupancy trial.

IMO there's no way to progress other than doing more clinical trials with different dosage and frequency.

The target occupancy trial and XanaHES both suggest 20mg.
The half life suggests 10mg twice daily or 20mg slow release.

I agree this is a risky investment.